Patients treated with sorafenib were younger, with higher AFP levels, higher proportion of diffuse/infiltrative tumor, more advanced portal vein invasion, and distant metastasis when compared with those that received TACE (Table 1). This evidence concerns the gene AFP and neoplasm.